Literature DB >> 3743092

Loss of patients in clinical trials that measure long-term survival following myocardial infarction.

R Bhaskar, D Reitman, H S Sacks, H Smith, T C Chalmers.   

Abstract

Loss of patients from clinical trials can nullify adequate randomization if the loss is unequally distributed among treatment groups. This study was designed to assess the magnitude of the problem in randomized control trials evaluating long-term therapy for survivors of myocardial infarction (MI). Only 19 of 52 trials reported having an explicit policy on withdrawals in the design stage; only 2 reported blinding the decision for withdrawal and only 7 reported accounting for withdrawals in sizing. In addition, only 16 gave the reader enough information to calculate the effect of withdrawals on trial results. In 2 of these 16 trials a p less than 0.05 result obtained by including withdrawals (intention to treat method) was reduced to p less than 0.05 when withdrawals were excluded. It is evident that many long-term trials do not contain adequate data on withdrawals. Readers of published trials are seldom able to judge whether or not withdrawals might affect the final results.

Entities:  

Mesh:

Year:  1986        PMID: 3743092     DOI: 10.1016/0197-2456(86)90029-2

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  3 in total

Review 1.  Recruitment and retention of patients into emergency medicine clinical trials.

Authors:  Stacey S Cofield; Robin Conwit; William Barsan; James Quinn
Journal:  Acad Emerg Med       Date:  2010-10       Impact factor: 3.451

2.  A trial of individual dose intensity and relative performance factors in tegafur maintenance chemotherapy for head and neck cancer.

Authors:  S Sawaki; H Watanabe; T Shin; T Kubota; S Komiyama; T Umezaki; I Nahm
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

3.  Attrition in longitudinal randomized controlled trials: home visits make a difference.

Authors:  Janey C Peterson; Paul A Pirraglia; Martin T Wells; Mary E Charlson
Journal:  BMC Med Res Methodol       Date:  2012-11-23       Impact factor: 4.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.